Waypoint Bio raised $20 million in Series A funding to run three CAR-T trials in China, using the country’s clinical testing environment to advance cell therapy candidates. The company described its strategy as leveraging China pathways for faster progression across multiple studies. The funding supports execution of trial sites, patient enrollment, and operational scaling for cell therapy programs. With CAR-T competition accelerating globally, geographic development plans are increasingly tied to speed and cost of getting into clinical evidence generation. Investors will watch trial design and endpoints closely for signals of efficacy, manufacturing feasibility, and safety as the programs initiate.